Aurobindo Pharma Gets USFDA Approval for Generic Cancer Drug

By By Rediff Money Desk, New Delhi
Dec 05, 2024 16:30
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, has received USFDA approval to market Pazopanib Tablets (200 mg) in the US. The drug is therapeutically equivalent to Novartis' Votrient tablets and is expected to launch in Q4FY25.
New Delhi, Dec 5 (PTI) Aurobindo Pharma on Thursday said its subsidiary has received approval from the US health regulator to market a cancer treatment medication in the US.

Eugia Pharma Specialities, a wholly-owned unit of the company, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets (200 mg) in the US market, the Hyderabad-based drug maker said in a regulatory filing.

The company's product is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Votrient tablets (200 mg), it added.

The product is expected to be launched in Q4FY25, the drug maker said.

According to IQVIA data, the product has an estimated market size of USD 106 million for the 12-month period ended October 2024.

Pazopanib Tablets, 200 mg are indicated for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.

Shares of Aurobindo Pharma on Thursday ended 0.98 per cent lower at Rs 1,245.70 apiece on the BSE.
Source: PTI
Read More On:
aurobindo pharmausfdageneric cancer drugpazopanib tabletsvotrient
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Maxivision Eye Hospitals Expands in Gujarat,...

Maxivision Super Specialty Eye Hospitals is expanding its presence in Gujarat with a Rs...

Senco Gold Raises Rs 459 Crore via QIP

Senco Gold Limited raised Rs 459 crore through a Qualified Institutions Placement (QIP)...

Eleganz Interiors Files IPO on NSE Emerge

Eleganz Interiors, a leading interior fit-out solutions provider, has filed IPO papers...

China to Invest USD 1 Billion in Pakistan...

China pledges USD 1 billion to establish a medical city in Pakistan, further...

Worldwide Realty Invests Rs 320 Cr in Haryana...

Worldwide Realty is investing Rs 320 crore to develop a 22-acre housing project in...

Dak Sewa is Jan Sewa: India Post to Go Digital,...

India Post is undergoing a digital transformation to become a leading logistics...

E-commerce Safety Pledge: Protecting Online...

Major e-commerce platforms in India commit to a Safety Pledge on Dec 24, aiming to...

Ira Bindra Named Group President of Reliance...

Mukesh Ambani appoints Ira Bindra as Group President for human resources at Reliance...

Zepto Cuts Losses, Revenue Doubles in FY24

Quick commerce firm Zepto narrowed its losses to Rs 1,248.6 crore in FY24, while...

KKR Sells 2.6% Stake in India Grid Trust for Rs...

Private equity firm KKR has sold a 2.6% stake in India Grid Trust for Rs 277 crore...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2024 Rediff.com